Is the relapse rate high after stopping tazetostat?

Tazemetostat is an oral drug that targets epigenetic regulation. It mainly acts on EZH2 methyltransferase and can inhibit the abnormal differentiation and proliferation of tumor cells. It has shown good disease control in the treatment of EZH2 mutant or wild-type follicular lymphoma (FL; non-Hodgkin lymphoma) and epithelioid sarcoma (ES; soft tissue sarcoma). However, one of the biggest challenges of targeted drugs is "relapse after drug withdrawal", which is also the most worrying issue for many patients in the late stage of efficacy.

From a mechanism perspective, tazerestat itself is not a cytotoxic drug, but an epigenetic inhibitor that regulates cell fate. Its role is not to kill all cancer cells, but to delay the progression of the disease by repairing or inhibiting malignant pathways. Therefore, once the drug is discontinued, especially if deep remission is not achieved or maintained for a sufficient period of time, residual lesions or abnormal cells may reactivate, leading to disease rebound or recurrence. This recurrence may be more common in some EZH2 mutation-positive patients because the mutation pathway remains the dominant driver of the disease.

However, this does not mean that all patients will relapse after stopping the drug. Some patients have achieved relatively durable disease control during treatment, and their condition can remain stable even if the treatment is stopped for a period of time. Individual differences, type of genetic mutation, time to start treatment, total duration of medication, and whether it is combined with other treatments will all affect the risk of relapse after discontinuation of medication. In addition, if patients are regularly monitored while taking tazetostat and early signs of biological recurrence are detected, they may also have the opportunity to intervene in time to avoid rapid progression of the disease.

To reduce the risk of recurrence, it is generally clinically recommended to continue treatment until disease progression or unacceptable toxicity occurs without obvious adverse effects. Even if discontinuation of medication is considered, it should be gradually adjusted under the supervision of a doctor, and changes in the condition should be followed closely.

Reference materials:https://www.tazverik.com/